Publication & Citation Trends
Most Cited Works
Publications
13 total
1225 AZD8931, an equipotent, reversible inhibitor of erbB1, erbB2 and erbB3 receptor signalling: characterisation of pharmacological profile
Cited by 0
OpenAlex
Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile
Cited by 0
OpenAlex
Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration
Cited by 2
OpenAlex
Biologically driven interpretation reveals molecular signatures predictive of oncogenic addiction to MEK signaling and cell line response to the MEK1/2 inhibitor AZD6244 (ARRY-142886)
Cited by 1
OpenAlex
ChemInform Abstract: Novel 3‐Alkoxy‐1H‐pyrazolo[3,4‐d]pyrimidines as EGFR and erbB2 Receptor Tyrosine Kinase Inhibitors.
Cited by 0
OpenAlex
Novel 3‐Alkoxy‐1H‐pyrazolo[3,4‐d]pyrimidines as EGFR and erbB2 Receptor Tyrosine Kinase Inhibitors.
Cited by 16
Semantic Scholar
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors PDF
Cited by 75
OpenAlex
The impact of ZD4054, a specific endothelin A receptor antagonist, on tumor blood supply, invasion, and the bone microenvironment
Cited by 2
OpenAlex
Research Topics
HER2/EGFR in Cancer Research
(5)
Colorectal Cancer Treatments and Studies
(4)
Quinazolinone synthesis and applications
(4)
Synthesis and biological activity
(3)
Lung Cancer Treatments and Mutations
(3)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Cancer Research UK
AstraZeneca (France)